Hope for Dobermanns

The results of the PROTECT trial investigating the efficacy of the drug pimobendan in Dobermanns with sub-clinical heart disease (disease with no symptoms) has now been published. Dogs on the trial that were receiving pimobendan (Vetmedin) lived longer without showing symptoms of the disease, and lived longer overall as well. Asymptomatic dogs can be screened for the disease by echocardiography. For more information call Sarah at the surgery.

- Return to News -